| Literature DB >> 29881282 |
Jan Máca1, Matúš Peteja2, Petr Reimer1, Ondřej Jor1, Věra Šeděnková1, Lucie Panáčková1, Peter Ihnát2, Michal Burda3, Pavel Ševčík1.
Abstract
BACKGROUND: Major abdominal surgery (MAS) is high-risk intervention usually accompanied by tissue injury leading to a release of signaling danger molecules called alarmins. This study evaluates the surgical injury caused by two fundamental types of gastrointestinal surgical procedures (open surgery and laparoscopy) in relation to the inflammation elicited by alarmins. PATIENTS AND METHODS: Patients undergoing MAS were divided into a mixed laparoscopy group (LPS) and an open surgery group (LPT). Serum levels of alarmins (S100A8, S100A12, HMGB1, and HSP70) and biomarkers (leukocytes, C-reactive protein [CRP], and interleukin-6 [IL-6]) were analyzed between the groups. The secondary objectives were to compare LPT and LPS cancer subgroups and to find the relationship between procedure and outcome (intensive care unit length of stay [ICU-LOS] and hospital length of stay [H-LOS]).Entities:
Keywords: alarmins; gastrointestinal surgery; laparoscopy; major surgery; open surgery; surgical injury
Year: 2018 PMID: 29881282 PMCID: PMC5985784 DOI: 10.2147/TCRM.S153359
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Figure 1CONSORT diagram of the study selection process.
Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; LPS, laparoscopy; LPT, open surgery (laparotomy).
Baseline, clinical, surgical, and outcome characteristics
| LPT | LPS | All | ||
|---|---|---|---|---|
| General characteristics | ||||
| n | 31 | 51 | 82 | |
| Age, years | 64 (50.5–71) | 63 (55.5–69.5) | 63 (53.5–70) | 0.90 |
| Sex, male | 21 (68%) | 34 (67%) | 55 (67%) | 1.00 |
| Body weight, kg | 82 (70.5–85) | 80 (67.5–90.5) | 80 (68.5–89.5) | 0.96 |
| Height, cm | 172 (168–180) | 174 (167–178) | 173 (167.25–178.75) | 0.89 |
| Body mass index, kg/m2 | 25.95 (23.62–30.11) | 27.44 (23.92–29.39) | 26.33 (23.82–29.93) | 0.77 |
| Clinical and surgical characteristics | ||||
| ASA | 2 (2–3) | 2 (2–3) | 2 (2–3) | 0.62 |
| ASA I | 3 (10%) | 3 (6%) | 6 (7%) | 0.67 |
| ASA II | 14 (45%) | 27 (54%) | 41 (51%) | 0.50 |
| ASA III | 10 (32%) | 18 (36%) | 28 (35%) | 0.81 |
| ASA IV | 4 (13%) | 2 (4%) | 6 (7%) | 0.20 |
| APACHE II | 6.5 (5–10.5) | 7 (5–10) | 7 (5–10.25) | 0.91 |
| SOFA (day 1) | 0 (0–2.75) | 1 (0–3.75) | 1 (0–3) | 0.42 |
| SOFA (day 2) | 0 (0–1.25) | 1 (0–3) | 1 (0–3) | 0.07 |
| SOFA (day 3) | 0 (0–1) | 1 (0–3) | 1 (0–3) | 0.15 |
| SIRS | 29 (94%) | 47 (92%) | 76 (93%) | 1.00 |
| Sepsis | 4 (13%) | 2 (4%) | 6 (7%) | 0.19 |
| Cancer | 18 (58%) | 47 (92%) | 65 (79%) | <0.001 |
| Surgery, min | 220 (180–265) | 320 (240–385) | 275 (210–360) | <0.001 |
| Blood loss, mL | 300 (100–525) | 600 (175–1,050) | 425 (100–1,000) | 0.04 |
| Blood products (EBR), mL | 0 (0–125) | 0 (0–550) | 0 (0–537.5) | 0.35 |
| Blood products (FFP), mL | 0 (0–0) | 0 (0–555) | 0 (0–509) | 0.17 |
| Vasopressors | 11 (35%) | 20 (39%) | 31 (38%) | 0.82 |
| Inotropes | 7 (23%) | 13 (25%) | 20 (24%) | 1.00 |
| Fluids, mL | 2,900 (2,200–4,000) | 4,000 (2,500–4,850) | 3,500 (2,500–4,500) | 0.03 |
| Mechanical ventilation after surgery | 7 (23%) | 13 (25%) | 20 (25%) | 1.00 |
| Body temperature at admission, °C | 35.9 (35.8–36.2) | 35.9 (35.6–36.1) | 35.9 (35.7–36.2) | 0.75 |
| Outcome | ||||
| Complications after surgery | 8 (26%) | 23 (45%) | 31 (38%) | 0.45 |
| Clavien Dindo Classification, yes | ||||
| Minor | 3 (10%) | 11 (22%) | 14 (17%) | 0.23 |
| Major | 5 (16%) | 12 (23%) | 17 (21%) | 0.58 |
| ICU-LOS, days | 4 (3–11.5) | 6 (4–8) | 6 (4–8) | 0.29 |
| Hospital LOS, days | 15 (9–24) | 16 (11–27) | 16 (10–25.25) | 0.36 |
| 30-Day mortality | 1 (3%) | 6 (12%) | 7 (9%) | 0.27 |
| In-hospital mortality | 2 (6%) | 7 (14%) | 9 (11%) | 0.47 |
Notes: The qualitative variables are expressed as n (%) and quantitative variables as the median (25th–75th percentile).
Administered during surgery.
Abbreviations: ASA, American Society of Anesthesiology; APACHE, Acute Physiology and Chronic Health Evaluation; EBR, erythrocyte concentrate without buffy coat; FFP, fresh frozen plasma; ICU, intensive care unit; LOS, length of stay; LPS, laparoscopy; LPT, open surgery (laparotomy); SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment.
The description of surgical interventions according to the place of resection (upper, middle, lower GIT) and the type of surgery (LPS, LPT), including the number of subjects
| GIT level | Type of surgery | LPT
| LPS
| All | ||
|---|---|---|---|---|---|---|
| Cancer | Noncancer | Cancer | Noncancer | |||
| Upper | Esophageal and gastric resection | 3 | 1 | 12 | 1 | 17 |
| Middle | Pancreatic (duodenopancreatic) and hepatic resection | 1 | 0 | 8 | 0 | 9 |
| Other small intestinal resections (cystectomy, status ileosus, gynecologic surgery) | 0 | 8 | 10 | 0 | 18 | |
| Lower | Large intestine and rectum resection | 14 | 4 | 17 | 3 | 38 |
Abbreviations: GIT, gastrointestinal tract; LPS, laparoscopy; LPT, laparotomy.
Serum levels of alarmins (S100A8, S100A12, HMGB1, and HSP70) and biomarkers (CRP, IL-6, albumin, and WBC) in the LPS and LPT groups three consecutive days after surgery
| LPT | LPS | ||
|---|---|---|---|
| S100A8, ng/m | L | ||
| Day 1 | 1.1 (0.98–1.7) | 1.24 (0.93–1.68) | 0.50 |
| Day 2 | 1.13 (0.86–1.99) | 1.45 (0.98–1.79) | 0.35 |
| Day 3 | 1.04 (0.83–1.62) | 1.21 (0.77–1.84) | 0.68 |
| S100A12, ng/m | L | ||
| Day 1 | 89.4 (75.2–101.35) | 93 (59–138.6) | 0.94 |
| Day 2 | 96.4 (86.8–116.5) | 120.3 (70.75–156.5) | 0.24 |
| Day 3 | 98.05 (76.88–122.75) | 110.5 (71.4–170.15) | 0.42 |
| HSP70, ng/m | L | ||
| Day 1 | 5.34 (4.21–7.33) | 7.64 (4.82–10.29) | 0.06 |
| Day 2 | 4.72 (3.46–7) | 5.3 (4.08–8.14) | 0.21 |
| Day 3 | 5.13 (3.42–6.46) | 4.68 (3.16–7.13) | 0.99 |
| HMGB1, U/m | L | ||
| Day 1 | 14 (4–46.5) | 12 (4–58.5) | 0.83 |
| Day 2 | 14 (4–36.5) | 11 (4–50.5) | 0.90 |
| Day 3 | 15.5 (4–40) | 10 (4–49.5) | 0.95 |
| WBC count, × | 109/L | ||
| Day 1 | 9.8 (8.5–11.8) | 9.9 (8.5–12.75) | 0.80 |
| Day 2 | 9.4 (6.65–12.65) | 10 (8.4–12.25) | 0.47 |
| Day 3 | 8.6 (5.9–12.15) | 8.6 (6.9–11.8) | 0.60 |
| CRP, mg/L | |||
| Day 1 | 115 (88–129.5) | 109 (73.5–135.5) | 0.96 |
| Day 2 | 181 (130.5–221) | 184 (141–212.5) | 0.82 |
| Day 3 | 146 (104.5–190) | 145 (114.5–214.5) | 0.33 |
| IL-6, ng/L | |||
| Day 1 | 111 (63.65–278.5) | 149 (110.5–281) | 0.13 |
| Day 2 | 69.1 (28.4–109.5) | 95.2 (54.9–155.5) | 0.03 |
| Day 3 | 31.3 (16.95–48.85) | 45.8 (23.45–93.5) | 0.04 |
Note: The variables are expressed as the median (25th–75th percentile).
Abbreviations: CRP, C-reactive protein; HMGB1, high mobility group box 1; HSP70, heat shock protein 70; IL-6, interleukin-6; LPS, laparoscopy; LPT, open surgery (laparotomy); WBC, white blood cell.
Figure 2The significant differences between LPS and LPT cancer subgroups related to proteins S100A8 and S100A12.
Abbreviations: LPS, laparoscopy; LPT, open surgery (laparotomy); NS, not significant.
Figure 3The significant differences between LPS and LPT cancer subgroups related to selected inflammatory biomarkers.
Abbreviations: IL-6, interleukin-6; LPS, laparoscopy; LPT, open surgery (laparotomy).